Co­herus craters af­ter Am­gen wins re­prieve on Neu­las­ta knock­off — FDA re­jects mar­ket­ing ap­pli­ca­tion

Shares of Co­herus $CHRS tum­bled 32% ear­ly Mon­day as news spread that the FDA has re­ject­ed its ap­pli­ca­tion for a biosim­i­lar of Am­gen’s Neu­las­ta. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA